Covaxin's makers could earn Rs 7,300 cr by vaccinating children

With a booster dose, the market of 12-18-year-olds represents a revenue pool as much as Rs 11,500 cr

Much before PM Narendra Modi called for vaccinating teenagers on ‘mission mode’,  thousands of young adults in the age group of 15-18 years, many in school uniforms flashing their student identity cards, were lining up at vaccination centres to get the first shot of the Covid vaccine. With Modi’s push likely to push reluctant parents of many of these young adults to get them inoculated, the jab’s makers seem to have tapped into a lucrative market for their product.

Bharat Biotech, the inventors and manufacturers of Covaxin, which is being administered to these young adults, could earn revenues of almost